Shilpa Medicare’s Unit VI cleared SFDA’s full GMP inspection with zero observations, boosting global credibility for oral films.

• The facility makes oral films, patches, and supplies to the US, Australia, and emerging markets, with EMA approval also secured.
• Inspection focused on Ondansetron Oral Film; no compliance issues found between February 18–20, 2025.
• Started as an API maker in 1987, Shilpa now offers full-spectrum pharma manufacturing and development services.